Liraglutide Improves Cognition in Alzheimer's Patients Despite Unchanged Cerebral Glucose Metabolism

Alzheimer's disease (AD) remains incurable, characterized by progressive neurodegeneration and cognitive decline. Current treatments offer symptomatic relief but do not halt disease progression. Preclinical studies have shown that glucagon-like peptide-1 (GLP-1) can enhance memory in AD-prone animal models, suggesting a potential neuroprotective role beyond its metabolic functions. This trial aimed to explore if liraglutide, a GLP-1 receptor agonist, could translate these preclinical observations into clinical benefits for AD patients by reducing amyloid deposition and improving symptoms.

The 'Evaluating liraglutide in Alzheimer’s disease' (ELAD) study was a multicenter, placebo-controlled clinical trial investigating the effects of liraglutide in patients diagnosed with Alzheimer's disease. Participants received a 6-month treatment regimen with either liraglutide or placebo. The primary outcome was the cerebral glucose metabolic rate, assessed to determine if liraglutide could modulate brain energy metabolism. Cognitive function was evaluated as a key secondary endpoint using the AD Assessment Scale-Executive domain (ADAS-Exec).

The ELAD trial revealed no significant differences in the primary outcome, cerebral glucose metabolic rate, between the liraglutide and placebo groups over the 6-month treatment period. This indicates that liraglutide did not directly alter overall brain glucose utilization in this patient cohort.

However, a notable finding was the improvement in cognition observed in the liraglutide-treated group, specifically as assessed by the AD Assessment Scale-Executive domain (ADAS-Exec). This suggests that liraglutide may exert its neuroprotective effects through mechanisms independent of global cerebral glucose metabolism, potentially involving pathways like neuroinflammation modulation, synaptic plasticity, or direct effects on neuronal survival.